{"id":"W4212977599","doi":"10.1200/jco.2022.40.6_suppl.011","title":"PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Internal medicine; Hazard ratio; Clinical endpoint; Placebo; Androgen deprivation therapy; Abiraterone acetate; Oncology; Interim analysis; Progression-free survival; Prednisone; Olaparib; Confidence interval; Docetaxel; Randomized controlled trial; Urology; Androgen receptor; Cancer; Chemotherapy; Pathology; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002067957,0.000179425,0.001276572,0.0001301689,0.0001670934,0.0000167947,0.00009499619,0.00008918902,0.0001281235],"category_scores_gemma":[0.0005850174,0.0001072,0.0001500525,0.0001424617,0.0003466796,0.0001281626,0.00004961057,0.0005653065,3.678352e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001847706,"about_ca_system_score_gemma":0.002281688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001072449,"about_ca_topic_score_gemma":0.0001842552,"domain_scores_codex":[0.996994,0.0003500202,0.001558403,0.0002633593,0.0005597472,0.0002744948],"domain_scores_gemma":[0.9960846,0.001510741,0.001383523,0.0001328611,0.0005840678,0.0003041555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8952937,0.006251315,0.002856368,0.0001128794,0.00118956,0.0001713435,0.0005075801,0.00003621525,0.0003361076,0.00002565219,0.0005217629,0.09269755],"study_design_scores_gemma":[0.6835711,0.2865301,0.002515421,0.00007525712,0.000637426,0.00003642383,0.0003239261,0.0001365069,0.0003001748,0.00009248724,0.025669,0.0001121694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906515,0.001391601,0.00001407523,0.004279306,0.0006506784,0.002788339,0.0001099678,0.00000524932,0.0001092881],"genre_scores_gemma":[0.9938931,0.004094461,0.0007070857,0.000206852,0.0002797334,0.0002893639,0.0000317955,0.00002667273,0.0004709638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2802788,"threshold_uncertainty_score":0.4371488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1667641359119953,"score_gpt":0.4970009066430789,"score_spread":0.3302367707310836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}